Drug Trial Radar · NCT04238767
Dolutegravir in Real Life in Lesotho
Last checked: Nov 19, 2026Latest source record: May 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,433
Actual
Start
Feb 10, 2020
Primary completion
May 19, 2021
Study completion May 20, 2021
Sponsor
- Lead sponsor
- Swiss Tropical & Public Health InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- SolidarMed; Ministry of Health, Lesotho; District Health Management Team of Butha-Buthe, Lesotho; District Health Management Team of Mokhotlong, Lesotho; University of Basel
- First posted
- Jan 23, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DO-REAL is an observational cohort study assessing the large-scale roll-out of the antiretroviral drug dolutegravir (DTG) in Lesotho. DTG has been shown to have low side-effects and superior treatment outcomes for people living with HIV-1 when compared to other antiretroviral drugs currently in use in low-income countries. The use of DTG in first-line antiretroviral therapy (ART) regimens was recommended by the World Health Organisation in 2018 and adopted by the Ministry of Health in Lesotho in 2019. While DTG-based ART regimens have led to promising health outcomes in high-income and clinical trial settings, certain concerns remain regarding the risk of ART-experienced patients transitioning to a DTG-based ART regimen being placed on a functional monotherapy (increasing the otherwise low risk of viral resistance to DTG) as well as side-effects including psychological symptoms and weight gain. Thus, the DO-REAL study intends to address these concerns and provide data on health outcomes of HIV patients on DTG in a "real-life" high-prevalence setting.
Conditions
- HIV-1-infection
Interventions
DolutegravirDrug
Eligibility to receive DTG-based ART at enrolment (i.e., initiation or offer to initiate DTG-based ART)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Virologic outcomes after programmatic transition to DTG-containing regimensTime frame: 4 months after initiation of a DTG-containing regimen
- Quality of life screening score (change from baseline)Time frame: Change between time of initiation of a DTG-containing ART regimen and 4 months thereafter
- Depression screening score (change from baseline)Time frame: Change between time of initiation of a DTG-containing ART regimen and 4 months thereafter
- HIV symptom screening score (change from baseline)Time frame: Change between time of initiation of a DTG-containing ART regimen and 4 months thereafter
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Butha-Buthe Government Hospital
Butha-Buthe, Lesotho
Seboche Mission Hospital
Butha-Buthe, Lesotho
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.